Application study of different doses of cytarabine in the treatment of high-risk MDS
Objective To observe the clinical efficacy of different doses of cytarabine in the treatment of high-risk myelodysplastic syndrome(MDS).Methods This study will focus on 119 patients with medium to high-risk MDS admitted to our hospital from January 2021 to December 2022,and conduct a prospective,randomized controlled trial.Using the computer random grouping method,the enrolled patients were divided into a conventional group(59 cases)and a low-dose group(60 cases).Both groups were treated with a combination of cytarabine and azacitidine.The conventional group received a conventional dose of cytarabine,while the low-dose group received a low dose of cytarabine.All patients were followed up for one year after treatment,and the peripheral blood indicators,recent efficacy,metabolic indicators,tumor-related gene methylation rate,and treatment safety of the two groups were compared.Results Under different treatment regimens,the white blood cell(WBC)and platelets(PLT)of the low-dose group were(4.3±1.2)×109/L and(82.4±10.4)×109/L,slightly lower than the conventional group[(4.8±1.4)×109/L and(85.4±10.3)×109/L].The overall response rate of the low-dose group was 86.7%(52/60),slightly lower than the conventional group at 89.8%(53/59).The levels of ferritin,vitamin 12,and vitamin b9 in the low-dose group were(195.4±20.4)μg/L,(475.4±20.3)pg/L,(5.72±1.4)mg/L,slightly higher than the conventional group[(192.3±20.4)μg/L,(471.3±20.5)pg/L,(5.4±1.4)mg/L].The methy-lation rates of p15 and SOCS1 in the low-dose group were 6.7%(4/60)and 5.0%(3/60),slightly higher than the conventional group[3.4%(2/59)and 1.7%(1/59)](P＞0.05).The incidence of side effects related to low-dose drugs was 3.3%(2/60)lower than the conventional group 16.95%(10/59)(P＜0.05).Conclusion Lowdose cytara-bine as an adjuvant therapy for high-risk MDS can reduce the risk of drug-related side effects without affecting the patient's peripheral blood count,recent efficacy,metabolic indicators,or increasing the methylation rate of tu-mor related genes.
万方数据
维普
